Publikationen, an denen er mitarbeitet Ángela Gutiérrez Camino (38)

2024

  1. CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. LncRNA-en adierazpen aldakorrak haurren leuzemia linfoblastiko akutuan dituen inplikazioak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 43, pp. 191-207

  2. The Role of the Dysregulation of Long Non-Coding and Circular RNA Expression in Medulloblastoma: A Systematic Review

    Cancers, Vol. 15, Núm. 19

  3. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2022

  1. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma

    Pediatric Blood and Cancer, Vol. 69, Núm. 11

  2. MicroRNA-based therapeutic strategies for cancer

    MicroRNA: From Bench to Bedside (Elsevier), pp. 503-520

  3. lncRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review

    International journal of oncology, Vol. 60, Núm. 5

2021

  1. Meduloblastoma pediatrikoaren pronostikorako markatzaile molekularren identifikazioa

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 40, pp. 51-76

  2. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review

    Critical Reviews in Oncology/Hematology, Vol. 165

2020

  1. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

2019

  1. MiRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review

    Epigenomics, Vol. 12, Núm. 1, pp. 69-80

  2. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 564-569

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Osteosarkoma pediatrikoarekiko suszeptibilitatean inplikatuta dauden aldaera genetikoak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 34, pp. 59-82

  5. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

  6. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 19, Núm. 4, pp. 361-373

  7. Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish population

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5